Zacks Investment Research upgraded shares of TherapeuticsMD Inc (NASDAQ:TXMD) from a sell rating to a hold rating in a report issued on Wednesday morning.
According to Zacks, “TherapeuticsMD, Inc. is a specialty pharmaceutical company focused on creating branded prescription, generic prescription and over-the-counter products targeted exclusively for women. It is developing three advanced hormone replacement products designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies. TherapeuticsMD, Inc. is based in Boca Raton, Florida. “
Separately, Noble Financial reiterated a buy rating and set a $17.50 price target on shares of TherapeuticsMD in a research note on Monday, July 11th.
TherapeuticsMD (NASDAQ:TXMD) traded down 0.702% during trading on Wednesday, hitting $6.365. 103,190 shares of the company’s stock traded hands. TherapeuticsMD has a 12-month low of $5.18 and a 12-month high of $11.26. The firm’s 50-day moving average price is $6.71 and its 200 day moving average price is $7.67. The stock’s market cap is $1.25 billion.
TherapeuticsMD (NASDAQ:TXMD) last announced its quarterly earnings data on Thursday, August 4th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by $0.01. The business earned $4.40 million during the quarter, compared to analysts’ expectations of $5.63 million. TherapeuticsMD’s revenue for the quarter was down 8.3% on a year-over-year basis. During the same period in the previous year, the business earned ($0.16) EPS. Analysts anticipate that TherapeuticsMD will post ($0.43) earnings per share for the current fiscal year.
TherapeuticsMD Company Profile
TherapeuticsMD, Inc is a women’s healthcare product company. The Company’s segment is creating and commercializing products for women. It is focused on conducting clinical trials necessary for regulatory approval and commercialization of advanced hormone therapy pharmaceutical products. Its drug candidates are created using its SYMBODA hormone technology, which enables the administration of hormones with high bioavailability alone or in combination.